222 related articles for article (PubMed ID: 28689831)
1. Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome.
Guvenir H; Dibek Misirlioglu E; Capanoglu M; Buyuktiryaki B; Unal O; Toyran M; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(4):1156-1157. PubMed ID: 28689831
[No Abstract] [Full Text] [Related]
2. Shortened desensitization leading to a 2-year enzyme replacement therapy with elosulfase alfa.
Bekis Bozkurt H; Karakurt T; Cavkaytar O; Arga M
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):261-262. PubMed ID: 33992778
[No Abstract] [Full Text] [Related]
3. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization.
Arroabarren E; Aznal E; Anda M; Sanchez-Valverde F
Pediatr Allergy Immunol; 2019 Jun; 30(4):491-494. PubMed ID: 30817035
[No Abstract] [Full Text] [Related]
4. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Schweighardt B; Tompkins T; Lau K; Jesaitis L; Qi Y; Musson DG; Farmer P; Haller C; Shaywitz AJ; Yang K; O'Neill CA
Clin Ther; 2015 May; 37(5):1012-1021.e6. PubMed ID: 25487082
[TBL] [Abstract][Full Text] [Related]
5. Successful sebelipase alfa desensitization in a pediatric patient.
Kulhas Celik I; Kucukcongar Yavas A; Unal Uzun O; Siyah Bilgin B; Dibek Misirlioglu E; Gunduz M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):732-733. PubMed ID: 30053591
[No Abstract] [Full Text] [Related]
6. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).
Hendriksz CJ
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1521-1532. PubMed ID: 27855521
[TBL] [Abstract][Full Text] [Related]
7. Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
Long B; Tompkins T; Decker C; Jesaitis L; Khan S; Slasor P; Harmatz P; O'Neill CA; Schweighardt B
Clin Ther; 2017 Jan; 39(1):118-129.e3. PubMed ID: 27955919
[TBL] [Abstract][Full Text] [Related]
8. Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.
Harmatz PR; Mengel E; Geberhiwot T; Muschol N; Hendriksz CJ; Burton BK; Jameson E; Berger KI; Jester A; Treadwell M; Sisic Z; Decker C
Am J Med Genet A; 2017 Feb; 173(2):375-383. PubMed ID: 27774754
[TBL] [Abstract][Full Text] [Related]
9. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
Jones SA; Bialer M; Parini R; Martin K; Wang H; Yang K; Shaywitz AJ; Harmatz P
Pediatr Res; 2015 Dec; 78(6):717-22. PubMed ID: 26331768
[TBL] [Abstract][Full Text] [Related]
10. Sequential rapid oral desensitization to rifampin and moxifloxacin for the treatment of active mycobacterium tuberculosis.
Benken ST; Nyenhuis SM; Dunne S
J Allergy Clin Immunol Pract; 2017; 5(1):195-197. PubMed ID: 27838324
[No Abstract] [Full Text] [Related]
11. Is premedication a necessity before galsulfase replacement therapy?
Ercan N; Bostanci IB; Ozmen S; Ertugrul A
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):200-2. PubMed ID: 27346567
[No Abstract] [Full Text] [Related]
12. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
Lyseng-Williamson KA
BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032
[TBL] [Abstract][Full Text] [Related]
13. [Morquio disease (Mucopolysaccharidosis type IV-A): clinical aspects, diagnosis and new treatment with enzyme replacement therapy].
Politei J; Schenone AB; Guelbert N; Fainboim A; Szlago M
Arch Argent Pediatr; 2015 Aug; 113(4):359-64. PubMed ID: 26172013
[TBL] [Abstract][Full Text] [Related]
14. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial.
Hendriksz CJ; Giugliani R; Harmatz P; Mengel E; Guffon N; Valayannopoulos V; Parini R; Hughes D; Pastores GM; Lau HA; Al-Sayed MD; Raiman J; ; Yang K; Mealiffe M; Haller C
Mol Genet Metab; 2015 Feb; 114(2):178-85. PubMed ID: 25284089
[TBL] [Abstract][Full Text] [Related]
15. Elosulfase alfa: first global approval.
Sanford M; Lo JH
Drugs; 2014 Apr; 74(6):713-8. PubMed ID: 24700469
[TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.
Hendriksz C; Santra S; Jones SA; Geberhiwot T; Jesaitis L; Long B; Qi Y; Hawley SM; Decker C
Mol Genet Metab; 2018 Apr; 123(4):479-487. PubMed ID: 29526614
[TBL] [Abstract][Full Text] [Related]
17. Laronidase desensitization during stem cell transplant in a child with Hurler syndrome.
Rosenberg J; Jhaveri P; Kelbel T
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):377-8. PubMed ID: 26916445
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.
Hendriksz CJ; Burton B; Fleming TR; Harmatz P; Hughes D; Jones SA; Lin SP; Mengel E; Scarpa M; Valayannopoulos V; Giugliani R; ; Slasor P; Lounsbury D; Dummer W
J Inherit Metab Dis; 2014 Nov; 37(6):979-90. PubMed ID: 24810369
[TBL] [Abstract][Full Text] [Related]
19. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Solano Villarreal ML; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Berger KI; Slasor P; Matousek R; Jurecki E; Shaywitz AJ; Harmatz PR
Mol Genet Metab; 2016 Sep; 119(1-2):131-43. PubMed ID: 27380995
[TBL] [Abstract][Full Text] [Related]
20. Immune modulation in a patient with Morquio syndrome treated with enzyme replacement therapy.
Sun A; Alshuaibi W; Petroni D; Skoda-Smith S; Goldberg MJ; Hale S
J Allergy Clin Immunol Pract; 2018; 6(5):1749-1751. PubMed ID: 29426755
[No Abstract] [Full Text] [Related]
[Next] [New Search]
